What assessments and investigations are needed to monitor ankylosing spondylitis?

Monitoring Ankylosing Spondylitis

Disease monitoring of ankylosing spondylitis requires validated composite disease activity measures (BASDAI plus acute phase reactants or ASDAS), clinical assessments using the ASAS core set, laboratory testing (ESR/CRP), and imaging at appropriate intervals—not routine scheduled imaging. 1, 2

Disease Activity Assessment

Validated Composite Measures (Perform Regularly)

Use ASDAS (Ankylosing Spondylitis Disease Activity Score) as the preferred measure, calculated with CRP 1, 3. The ASDAS formula incorporates:

• Total back pain
• Patient global assessment
• Peripheral pain/swelling
• Duration of morning stiffness
• CRP (or ESR if CRP unavailable)

Alternatively, use BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) plus acute phase reactants 1. BASDAI assesses:

• Fatigue level
• Spinal pain (neck, back, hip)
• Peripheral joint pain/swelling
• Entheseal tenderness
• Morning stiffness severity and duration

The frequency of monitoring depends on disease activity level—measure more frequently when disease is active, less often when stable 1, 2.

ASAS Core Set Parameters (Document at Each Visit)

The ASAS core set provides a standardized framework 2:

• Physical function: BASFI (Bath Ankylosing Spondylitis Functional Index)
• Pain: VAS for spine pain at night and during the day
• Spinal mobility: Chest expansion, modified Schober test, occiput-to-wall distance, BASMI or lateral flexion
• Patient global assessment: VAS in past week
• Morning stiffness: Duration and severity
• Peripheral joints/entheses: Number of swollen joints, assessment of painful entheses
• Acute phase reactants: ESR (and/or CRP)
• Fatigue: VAS assessment

Laboratory Monitoring

Monitor CRP and/or ESR regularly 1, 4, 5. These acute phase reactants:

• Provide objective evidence of inflammation
• Correlate with disease activity
• Help guide treatment decisions
• Predict response to biologic therapy (elevated baseline inflammatory markers predict better anti-TNF response) 3

The 2019 ACR/SAA/SPARTAN guidelines conditionally recommend regular monitoring of CRP or ESR over usual care without such monitoring 4.

Imaging Surveillance

Conventional Radiography

For structural damage monitoring, obtain radiographs of the spine and sacroiliac joints no more frequently than every 2 years 2. Specifically:

• AP and lateral lumbar spine
• Lateral cervical spine
• AP pelvis (sacroiliac joints and hips)

More frequent imaging (minimum 6-month intervals) may be justified in rapidly progressing cases, but this is the exception 2. The 2019 ACR guidelines conditionally recommend against obtaining repeat spine radiographs at scheduled intervals as a standard approach 4.

MRI

MRI is not for routine scheduled monitoring 3, 5. Use MRI selectively:

• To assess disease activity when clinical assessment is unclear, particularly in patients on biologics with uncertain activity status 3, 4
• To predict treatment response: Extensive spinal bone marrow edema predicts good anti-TNF response and may aid in treatment decisions 3
• To predict structural progression: Vertebral corner inflammatory or fatty lesions predict new syndesmophyte development 3

STIR sequences are sufficient to detect inflammation; contrast is not needed for routine assessment 3. The PANLAR 2023 guidelines strongly recommend against routine MRI for follow-up 5.

Additional Monitoring Considerations

Extra-Articular Manifestations

Monitor for and document:

• Acute anterior uveitis
• Inflammatory bowel disease symptoms
• Psoriasis
• Cardiovascular comorbidities

Functional Assessment

Beyond BASFI, assess:

• Work disability
• Social participation
• Quality of life measures

Treatment-Specific Monitoring

When patients are on biologics or other DMARDs, adjust monitoring frequency based on:

• Treatment response
• Safety parameters
• Disease stability

Common Pitfalls to Avoid

1. Don't rely on imaging alone: Radiographic changes lag behind clinical disease activity by months to years
2. Don't use BASDAI without acute phase reactants: BASDAI is subjective; combining with CRP/ESR improves accuracy
3. Don't order routine MRIs: Reserve for specific clinical questions, not scheduled surveillance
4. Don't ignore patient-reported outcomes: Disease activity is multidimensional and cannot be captured by laboratory values alone
5. Don't use classification criteria for diagnosis: ASAS criteria are for research classification, not clinical diagnosis 6

The monitoring approach should be individualized based on disease severity, treatment intensity, and presence of poor prognostic factors (hip involvement, elevated ESR, young age at onset, poor NSAID response, peripheral arthritis, syndesmophytes at baseline) 2.